GlassScriptPhysician profile
Michael J Line
NPI 1518000587
$4,761.28
in general payments reported to CMS, 2019-2025
24 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,576 · 2024: $1,357 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,589 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,588.80 |
| Education | $172.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,336.16 | 2023-2025 | |
| Lundbeck LLC | $573.48 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $480.54 | 2023-2025 | |
| Pfizer INC. | $397.73 | 2023-2025 | |
| Lilly USA, LLC | $245.44 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Ucb, INC. | $242.30 | 2023-2025 | Fintepla, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $227.07 | 2023-2025 | Ajovy |
| Otsuka America Pharmaceutical, INC. | $201.55 | 2023-2025 | Nuedexta, Rexulti |
| Sk Life Science, INC. | $189.63 | 2023-2025 | Xcopri |
| Neurelis, INC. | $146.25 | 2023-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $118.33 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $91.34 | 2023-2024 | Aptiom |
| Takeda Pharmaceuticals U.S.A., INC. | $84.62 | 2024-2025 | Hyqvia |
| Axsome Therapeutics, INC. | $59.69 | 2025 | Symbravo |
| Merz Pharmaceuticals, LLC | $55.86 | 2024 | Xeomin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $52.71 | 2024-2025 | Tysabri, Vumerity, Avonex |
| Argenx US, INC. | $49.53 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $48.69 | 2023 | Inbrija |
| Impel Pharmaceuticals INC. | $47.64 | 2023 | Trudhesa |
| Novartis Pharmaceuticals Corporation | $37.67 | 2025 | |
| Scilex Pharmaceuticals INC. | $22.08 | 2023 | Ztlido |
| Amgen INC. | $19.81 | 2023 | Aimovig |
| Genzyme Corporation | $17.57 | 2023 | |
| Neurocrine Biosciences, INC. | $15.59 | 2023 | Ingrezza, Ongentys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Line listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.